If you want to get inside of your pet's head, the tech hasn't arrived yet, but one company hopes to have it trending in the right direction.

Los Angeles-based FluentPet has developed a series of tiles it claims help four-legged companions communicate with their humans. Through training, they can learn to associate various tiles with words they've learned over time and then use their paws to press them.  

The tech has been a hit on platforms like TikTok, where tons of "talking dog" videos have gone viral.

There are a wide range of options to select from when it comes to purchasing the tech. Test kits start out around $35 with the most expensive option, They Can Talk Kit, being priced around $230. 

The company also recently launched FluentPet Connect, which integrates the tile button system into an app. This helps keep pet owners connected to their pets at all times. If a person isn't home, their pet could send an alert, similar to a text message.

The system is available for an additional $69.99 but is compatible with tiles that have already hit the market.

However, devices like FluentPet and the studies that have been done with their subjects do face skepticism from scientists. Clive Wynne, the founding director of the Canine Science Collaboratory at Arizona State University, explained that rather than language comprehension, the dogs are being conditioned.

“This is one of the most basic forms of learning in the animal kingdom," Wynne told the Washington Post. "The dog forms an association between an action and an outcome that it desires.”

Share:
More In Business
Regeneron Joins Battle Against COVID-19, Releases Stats on New COVID Treatment
The world hit a grim milestone on Monday, with COVID-19 cases surpassing a quarter of a billion worldwide. As cases increase, the fight to beat the virus continues as well, with a number of medical breakthroughs coming out over the last few months in the form of pills from Pfizer and Merck. Regeneron is now the latest company to join the fight, recently releasing new data on a covid antibody cocktail. Professor Peter Pitts, former FDA Associate Commissioner and the founder of the Center for Medicine in the Public Interest breaks down the differences between the 3 treatments and why vaccines are still among the fire line of defense.
Peloton Stock Continues Steep Drop as It Loses More Than $10B in Value
Doug Astrop, managing partner at Exponential Investment Partners, joined Cheddar to discuss Peloton's precipitous price drop, and whether the company can recover as the at-home workout trend tapers off. "They've lowered the prices on their equipment to try to attract a bigger audience because ultimately they're sort of headed to this Apple ecosystem model where they can monetize a loyal customer base," he said. Astrop noted that he believes there is a reality where the in-person gym experience and Peloton's at-home programs can co-exist.
Markets Look to Continue Record Run
Bill Stone, Chief Investment Officer at Glenview Trust Company, joined Wake Up With Cheddar to break down markets headlines ahead of the start of the trading week.
Load More